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leukemia (AML) have only one treatment option: hemato-
poietic cell transplantation (HCT). Using cord blood (CB)-
derived stem cells, instead of cells from bone marrow cells or
peripheral blood, results in less relapses (increased anti-
tumor reactivity) and less graft-versus-host disease
(increased safety). Although this treatment is potentially
curative, still more than half of the children die from re-
lapses. We therefore aim to develop additional powerful and
safe CB-derived immunotherapies for pediatric AML. First,
we developed a dendritic cell (DC) vaccine, derived from the
CB stem cells with the goal to stimulate the anti-tumor
reactivity of the newly developing immune system in AML
patients after CB-HCT. CD34+ CB stem cells were expanded
and differentiated into DCs. CBDCs upregulated co-stimula-
tory molecules after maturation and showed enhanced
CCR7-dependent migration towards CCL19 in a trans-well
migrations assay. In addition, CBDCs expressed the tumor
antigen Wilms’ Tumor 1 (WT1) protein after electroporation
with WT1-mRNA. These WT1 expressing CBDCs were not
only able to stimulate T cells in a mixed lymphocyte reaction
but in an antigen-speciﬁc setting as well.
Second, we are testing additional immunotherapies that can
be used combined with CBDC vaccination, i.e. NK cells and
gamma delta T cells. All of which may either enhance the
immune stimulating function of the CBDCs, or can be acti-
vated by CBDCs to directly and/or indirectly target the AML
cells. As such, these addition immunotherapies will further
intensify the anti-tumor reactivity of CB-HCT and not only in
the AML setting but potentially also in several solid tumors.250
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Objectives: Up to one third of patients with acute myeloid
leukemia (AML) relapse following allogeneic hematopoietic
stem cell transplantation (SCT) in morphologic complete
remission (mCR). We hypothesized that that the cytogenetic
pattern of relapse is related to cytogenetic risk group at
diagnosis.
Methods: We analyzed the data from a cohort of patients
(n ¼ 45) with AML and abnormal cytogenetics who relapsed
following SCT in mCR. Cytogenetic abnormalities were
identiﬁed by ﬂuorescence in situ hybridization (FISH) and
metaphase cytogenetics.
Results: All transplants were performed using peripheral
blood stem cells. The mean (standard deviation) age of pa-
tients was 53 (15) years, and 47% were male. AML was
therapy-related in 8 (18%) patients. The most frequent FAB
subtypes were M0/M1/M2 (38%) and M4/M5 (38%). Favor-
able/Intermediate and unfavorable cytogenetic risk disease
was present in 11 (24%) and 34 (76%) patients, respectively.
Persistent cytogenetic abnormalities despite mCR were
present before SCT in 49% of patients. 84% of patients were in
CR1. Conditioning was myeloablative in 49% of patients. The
donor was a matched sibling, matched unrelated donor, or
haploidentical relative in 47%, 51%, and 2% of patients,
respectively. Primary graft failure did not occur in any pa-
tient. 29% and 4% of patients had CMV reactivation anddisease, respectively. Acute and chronic GvHD occurred in
27% and 13% of patients, respectively. The median time to
relapse and overall survival from the time of transplant were
3.5 (interquartile range: 1.7-5.3) and 10 (8.9-11.2) months,
respectively. Three patterns of relapse were identiﬁed: same
clone (n ¼ 23, 51%), subclone (n ¼ 17, 38%), and new clone (n
¼ 5, 11%). The latter two were grouped together during
analysis because both represented clonal evolution. The only
difference in the baseline and transplant characteristics be-
tween patients who relapsed with the same clone versus
those who relapsed with clonal evolution was cytogenetic
risk group. Speciﬁcally, patients with high risk cytogenetics
at diagnosis were more likely to relapse with the same clone
than those with low/intermediate risk cytogenetics (62% vs.
18%, respectively; P ¼ 0.017). There was no difference in
median time to relapse (same clone, 3.2 months vs. clonal
evolution, 3.5 months, P ¼ 0.67) or overall survival (9.4 vs
10.0 months, respectively; P ¼ 0.88) based on the type of
clone at the time of relapse.
Conclusions: In patients with AML and abnormal cytoge-
netics who undergo SCT in mCR, the same clone is respon-
sible for relapse in a signiﬁcantly higher proportion of those
with unfavorable risk cytogenetics at the time of AML diag-
nosis compared to those with favorable/intermediate risk
disease. This may be due to higher rates of minimal residual
disease after SCT in patients with unfavorable risk disease.
Next-generation sequencing may add ﬁner resolution to our
ﬁndings.251
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Background: CMML is a clonal hematopoietic stem cell
disorder with myelodysplastic and myeloproliferative over-
lap features and a high tendency to progress to acute leu-
kemia. Although treatment options include supportive care
and use of hypomethylating agents, allogenic hemopoietic
stem cell transplant (allo HCT) remains the only curative
option. We sought to evaluate outcomes in patients with
CMML that underwent allo HCT.
Methods: After IRB approval, consecutive adult patients with
CMML who underwent allo HCT from 1990 to 2014 were
identiﬁed and evaluated. All data were retrospectively
abstracted. Conditioning regimens, GVHD prophylaxis and
transfusions were according to institutional standards.
Results: Thirty-six patients (males 23%) who met WHO
criteria for CMML were included. The median age was 53
years (range, 18 to 66 years) and 20 patients (56%) had
CMML-1, while 16 patients (44%) had CMML-2. Patient dis-
tribution according to Mayo risk category was: 20 high-risk,
9 intermediate-risk and 7 low-risk while distribution ac-
cording to Spanish karyotype was: 9 high-risk, 7 interme-
diate-risk and 20 low-risk.
Twenty-two received myeloablative conditioning (me-
dian age: 49 years) and 14 received reduced-intensity con-
ditioning (median age: 59 years). At the time of transplant,
20 patients had received induction chemotherapy, 6 had
received hypomethylating agents and 10 were managed by
supportive care. Twenty-six patients (72%) experienced
acute graft-versus-host disease (GVHD) (15 grade II-IV) and
23 (64%) patients experienced chronic GVHD (11 severe).
Post-transplant complete remission was achieved in 25
Table 1
Variable n Mean (STD) Median (range)
Age (yr) 42 57.1 (11.5) 59.5 (29, 71)
Early marrow blast % 42 21.4 (27.1) 6 (0, 90)
Factor Frequency Factor Frequency
Secondary AML Cytogenetics
N 33 Favorable/intermediate 1/16
Y 9 Unfavorable/unknown 23/2
FLT3 NPM
Negative 20 Negative 25
Positive 9 Positive 2
# of inductions MRD present
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diedwhile 18 (50%) had relapse-free survival. Median follow-
upwas 17months (range 0.7- 191months) and at last follow-
up, 23 (64%) deaths were documented (8 disease relapse, 13
non-relapse mortality, 2 lost to follow-up). Most common
causes of non-relapse mortality were complications related
to GVHD (31%) and sepsis (31%). In a survival analysis,
engraftment failure and high HCT-comorbidity index had a
trend towards shortened overall survival.
Conclusions: Allogeneic HCT remains a viable treatment
option for patients with CMML, with engraftment failure and
high co-morbidity index being potential poor prognostica-
tors impacting survival. Conventional risk stratifying CMML
models did not predict for HCT outcomes.Figure 1. Survival as a function of early marrow blast percentage
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Introduction: The effect of early response of AML to induc-
tion chemotherapy on transplant outcomes is not well-
characterized. We hypothesize that higher blast count in an
early post-induction bonemarrow biopsy (Day 14marrow) is
associated with inferior outcomes after allogeneic HCT for
AML in ﬁrst remission (CR1).
Methods: We retrospectively reviewed 42 AML patients
(median age 60 years, range 29-71) treated at Seidman
Cancer Center from 2008 to 2014 who had early marrow
evaluation (median 13 days, range 7-14) after induction
chemotherapy and received allogeneic transplant in CR1.
Blast % was calculated from 200 total nucleated cells counted
on marrow aspirate. Variables examined included age, per-
formance status, de novo vs. secondary AML, cytogenetics,
FLT3 / NPM status, incomplete count recovery (CRi), number
of induction cycles, conditioning regimen, graft source,
minimal residual disease (MRD) and presence of acute and
chronic graft-versus-host disease (GVHD). Relapse-free sur-
vival (RFS) was deﬁned as time from transplant to relapse or
death in remission. Survival distribution from time of
transplant was estimated using Kaplan-Meier methods and
difference of survival and RFS between groups was examined
by log-rank. Effect of continuous variables on survival was
estimated using Cox model.
Results: Patient characteristics are summarized in Table 1.
RFS at 2 years did not differ between those with <6% or
>5% marrow blasts at Day 14 (58 vs. 58%, p¼.7). Survival at
2 years also did not differ between the 2 groups (43 vs.
49%, p¼1; Figure 1). Use of different blast cutoff values did
not elicit a difference in 2-year RFS or survival. A higher
blast percentage did not result in increased hazard of death
(HR 1, p¼.72). Having 2 induction cycles (32 vs. 53%,
p¼.18), graft source of cord blood vs. other (28 vs. 58%;
p¼.16), and ECOG performance status 1 vs. 0 (27 vs. 42%;
p¼.32) may be associated with inferior survival at 2 years,
although this did not reach statistical signiﬁcance likely
due to limited sample size.
Conclusion: Apparent chemotherapy resistance based
on higher residual blast percent early after induction
chemotherapy likely carries no signiﬁcant risk of adverse
outcome after AML transplant in ﬁrst remission. Utility of theDay 14 marrow evaluation in predicting outcomes after
allogeneic transplant in CR1 remains unclear.253
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Clinical trials have shown the efﬁcacy of clofarabine (Clo),
ﬂudarabine (Flu) and busulfan (Bu) combinations in he-
matopoietic stem cell transplantation (HSCT) for myeloid
